Goldman Sachs Group Inc Verve Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

$596 Billion
Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,413,118 shares of VERV stock, worth $15.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,413,118

Previous 1,413,118 -0.0%

Holding current value

$15.6 Million

Previous $6.46 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	BUY	$4.57 - $8.63 $3.07 Million - $5.8 Million	671,939 Added 90.66%	1,413,118 $6.46 Million
Q4 2024 Feb 11, 2025	SELL	$4.5 - $7.19 $1.38 Million - $2.21 Million	-306,887 Reduced 29.28%	741,179 $4.18 Million
Q3 2024 Nov 14, 2024	SELL	$4.4 - $7.86 $1.06 Million - $1.89 Million	-240,183 Reduced 18.64%	1,048,066 $5.07 Million
Q2 2024 Aug 13, 2024	BUY	$4.76 - $12.79 $2.18 Million - $5.85 Million	457,379 Added 55.05%	1,288,249 $6.29 Million
Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $3.86 Million - $6.42 Million	357,254 Added 75.43%	830,870 $11 Million
Q4 2023 Feb 13, 2024	BUY	$8.84 - $18.7 $2.37 Million - $5.01 Million	268,079 Added 130.43%	473,616 $6.6 Million
Q3 2023 May 14, 2024	SELL	$11.42 - $20.82 $3.06 Million - $5.58 Million	-268,079 Reduced 56.6%	205,537 $2.73 Million
Q3 2023 Nov 14, 2023	SELL	$11.42 - $20.82 $702,798 - $1.28 Million	-61,541 Reduced 23.04%	205,537 $2.73 Million
Q2 2023 May 14, 2024	BUY	$13.34 - $19.9 $55,160 - $82,286	4,135 Added 1.57%	267,078 $5.01 Million
Q2 2023 Aug 14, 2023	BUY	$13.34 - $19.9 $55,160 - $82,286	4,135 Added 1.57%	267,078 $5.01 Million
Q1 2023 May 14, 2024	SELL	$14.3 - $24.01 $1.88 Million - $3.15 Million	-131,291 Reduced 33.3%	262,943 $3.79 Million
Q1 2023 May 11, 2023	SELL	$14.3 - $24.01 $1.88 Million - $3.15 Million	-131,291 Reduced 33.3%	262,943 $3.79 Million
Q4 2022 May 14, 2024	BUY	$17.85 - $40.7 $1.62 Million - $3.7 Million	90,881 Added 29.96%	394,234 $7.63 Million
Q4 2022 Feb 13, 2023	BUY	$17.85 - $40.7 $1.62 Million - $3.7 Million	90,881 Added 29.96%	394,234 $7.63 Million
Q3 2022 May 14, 2024	BUY	$15.63 - $41.49 $3.57 Million - $9.48 Million	228,594 Added 305.77%	303,353 $10.4 Million
Q3 2022 Nov 10, 2022	BUY	$15.63 - $41.49 $3.57 Million - $9.48 Million	228,594 Added 305.77%	303,353 $10.4 Million
Q2 2022 May 14, 2024	SELL	$11.14 - $23.17 $4.44 Million - $9.24 Million	-398,857 Reduced 84.22%	74,759 $1.14 Million
Q2 2022 Aug 15, 2022	SELL	$11.14 - $23.17 $352,124 - $732,380	-31,609 Reduced 29.72%	74,759 $1.14 Million
Q1 2022 May 16, 2022	BUY	$20.92 - $39.36 $1.13 Million - $2.12 Million	53,968 Added 102.99%	106,368 $2.43 Million
Q4 2021 Feb 14, 2022	BUY	$31.94 - $54.82 $327,257 - $561,685	10,246 Added 24.31%	52,400 $1.93 Million
Q3 2021 Nov 10, 2021	BUY	$46.0 - $73.99 $1.94 Million - $3.12 Million	42,154 New	42,154 $1.98 Million

Others Institutions Holding VERV

# of Institutions

203

Shares Held

79.5M

Call Options Held

204K

Put Options Held

101K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $663M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Verve Therapeutics, Inc. Transaction History